Loading
Stool transplants from immunotherapy responders have rescued some non-responders in melanoma. If defined bacterial cocktails work as well, every immunotherapy patient could get one.
This idea proposes microbiome transplant as a routine immunotherapy adjunct: stool from responders has rescued some non-responders in Melanoma, and defined bacterial cocktails could reach every immunotherapy patient. Phase 1/2 FMT studies (Davar, Baruch) converted a fraction of refractory melanoma patients, defined consortia (SER-155, VE800) and diet trials are ongoing, and durability is unclear. The hypothesis is that a defined consortium with first-line PD-1 blockade raises the response rate in melanoma and Non-small-cell lung cancer, supported by causal FMT data and the harm done by antibiotics. The test is a placebo-controlled phase 2/3, and the idea sits within the Microbiome-tumour interactions pathway and the hallmark Polymorphic microbiomes.
One trial page, one technology page, one pathway page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One trial page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for KRAS in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for PD-1 in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.
Shares CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, CheckMate 915, RELATIVITY-098, Fianlimab + cemiplimab phase 3 (first-line melanoma) and the tags mechanism, open-question.
Shares Gustave Roussy, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1 and the tags mechanism, open-question.
Shares MD Anderson Cancer Center, Non-small-cell lung cancer and the tags mechanism, open-question.
Shares Melanoma, Non-small-cell lung cancer and the tags mechanism, open-question.
Shares MD Anderson Cancer Center and the tags mechanism, open-question.
Shares Melanoma and the tags mechanism, open-question.
Shares Non-small-cell lung cancer and the tags mechanism, open-question.
Shares Non-small-cell lung cancer and the tags mechanism, open-question.